Prednisolone — How Dangerous It Is, Side Effects and Withdrawal Syndrome

EFFECTIVE | TOXIC

What Names Prednisolone Is Known Under

The international nonproprietary name is prednisolone. Documents and search queries may use the names Prednisolone, Prednisolon, prednisolone, prednisolone acetate, prednisolone sodium phosphate, and prednisolone sodium succinate. Dosage forms include tablets, oral solution, injectable preparations, eye drops and suspensions, ointments, and other topical formulations. International brand names include Deltacortril, Deltastab, Pevanti, Orapred, Prelone, Millipred, Pediapred, Pred Forte, and Omnipred; the availability of specific brands varies by country. Prednisone is not a brand name for prednisolone but a separate prodrug that is converted to prednisolone in the liver. They must not be regarded as two independent glucocorticosteroids when used simultaneously: their pharmacological burden is additive.

Prednisolone is also included in combination ophthalmic, otic, and topical products together with antibiotics and antiseptics such as neomycin, polymyxin B, chloramphenicol, or sulfacetamide. A patient may be taking tablets while simultaneously using drops, an ointment, an inhaled or injectable glucocorticosteroid without realizing that this duplicates glucocorticoid therapy. The systemic effect of topical formulations is usually lower, but it increases when they are applied over large areas, to damaged skin, under occlusive dressings, for prolonged periods, or when several formulations are used together.

Why Prednisolone Is Considered Harmless and Where the Real Risk Begins

Prednisolone rapidly reduces pain, swelling, itching, shortness of breath, and inflammation, which can create the impression that it is a medication that “simply relieves a flare-up.” Symptoms may indeed disappear within hours or days, but carbohydrate metabolism, blood pressure, fluid and electrolyte balance, immune response, bone metabolism, and hypothalamic-pituitary-adrenal function are changing at the same time. A person notices relief before toxicity.

The main everyday mistake is judging safety by the absence of an immediate reaction. Increased glucose, sodium retention, potassium loss, sleep disturbances, and suppression of immune defenses can develop without marked pain. Repeated “short” courses gradually add up to a substantial cumulative glucocorticoid burden. Additional risk arises from simultaneous use of prednisone, dexamethasone, methylprednisolone, corticosteroid inhalers, ointments, and intra-articular injections.

Prednisolone is not an ordinary pain reliever or antiallergic medication. It interferes with hormonal regulation and suppresses the inflammatory response, including reactions required to limit infections. Therefore, feeling better does not always mean that the underlying cause of the disease has been eliminated.

Side Effects During Short-Term Use

Common reactions during the first hours and days include increased appetite, heartburn, stomach discomfort, fluid retention, elevated blood pressure, insomnia, agitation, anxiety, irritability, and mood changes. In patients with diabetes or prediabetes, glucose levels may rise noticeably from the beginning of treatment. Acne, sweating, headache, and reduced salt tolerance may occur.

Clinically significant early complications include marked hyperglycemia, hypokalemia, decompensation of heart failure due to sodium and water retention, exacerbation of ulcerative gastrointestinal disease, increased intraocular pressure, and masking of an infectious process. The risk of gastrointestinal injury increases particularly when prednisolone is combined with nonsteroidal anti-inflammatory drugs.

Psychiatric reactions may develop even after the start of a short course. Severe insomnia, emotional lability, depression, hypomania, mania, confusion, hallucinations, and steroid psychosis are possible. There is a dose relationship, but an individual patient’s response cannot be predicted in advance.

Life-threatening conditions include anaphylaxis, severe hyperglycemic decompensation, acute psychosis with dangerous behavior, serious infection, gastrointestinal bleeding, and severe electrolyte disturbances. A glucocorticosteroid can reduce fever and pain, so an infection may sometimes progress despite an apparent “improvement.”

Consequences of Long-Term and Repeated Use

Treatment lasting weeks or months produces a characteristic complex of metabolic and hormonal disturbances: increased appetite and body weight, redistribution of adipose tissue, rounding of the face, fat accumulation around the trunk and neck, thinning of the skin, striae, easy bruising, and delayed wound healing. Steroid-induced diabetes mellitus, arterial hypertension, dyslipidemia, and persistent edema may develop.

Prednisolone accelerates bone loss, reduces calcium absorption, increases calcium excretion, and suppresses bone formation. The consequences include glucocorticoid-induced osteoporosis, vertebral compression fractures, and fractures of the proximal femur. A separate severe complication is aseptic necrosis of the femoral or humeral head; it may continue to progress even after glucocorticoid therapy has been discontinued.

Protein catabolism leads to loss of muscle mass, weakness, and steroid myopathy. Proximal muscles are usually affected most severely: a person may find it difficult to rise from a chair, climb stairs, or keep the arms raised. In severe cases, weakening of the respiratory muscles can further worsen the course of bronchopulmonary disease.

Ocular complications may include posterior subcapsular cataract, increased intraocular pressure, and glaucoma. Immunosuppression increases susceptibility to bacterial, viral, fungal, and parasitic infections, as well as reactivation of latent infections. The clinical picture may be less obvious because prednisolone simultaneously suppresses inflammatory symptoms.

The main hormonal risk is suppression of endogenous cortisol secretion. The higher the dose, the longer the treatment, and the more frequently courses are repeated, the greater the likelihood of suppression of the hypothalamic-pituitary-adrenal axis. After discontinuation, recovery may take from several weeks to many months and varies substantially between patients. The absence of prominent early adverse effects does not prove that adrenal function has been preserved.

Contraindications and High-Risk Groups

Absolute contraindications to systemic formulations include hypersensitivity and systemic fungal infections, unless the glucocorticosteroid is being used as part of specialist treatment for a dangerous condition. Immunosuppressive doses are incompatible with administration of live vaccines because of the risk of uncontrolled infection.

In an active bacterial, viral, fungal, or parasitic infection, prednisolone may accelerate dissemination of the pathogen while simultaneously masking fever and inflammatory signs. Tuberculosis, infections caused by Strongyloides stercoralis, herpetic eye disease, and recently resolved severe infections require particular attention.

In diabetes mellitus, the medication may cause abrupt decompensation of glycemic control. In uncontrolled hypertension, heart failure, edematous states, and kidney disease, sodium and fluid retention increases the burden on the cardiovascular system. In hypokalemia, the risk of muscle weakness and cardiac rhythm disturbances increases.

In peptic ulcer disease, diverticulitis, recent intestinal anastomoses, and concomitant use of NSAIDs, the risk of perforation or bleeding increases. Prednisolone may reduce pain and signs of peritoneal irritation, causing a dangerous complication to be recognized later.

In osteoporosis, a history of low-energy fractures, marked underweight, and a high risk of falls, accelerated bone loss is particularly dangerous. In glaucoma, cataract, and herpetic keratitis, glucocorticoid therapy may worsen the condition of the eyes.

Patients with psychosis, bipolar disorder, severe depression, or pronounced psychiatric reactions during a previous course require especially careful assessment. During pregnancy, the decision depends on the indication, dose, and duration of treatment: potential risk does not mean an automatic prohibition, but self-prescribing is unacceptable.

Dangerous Interactions

Combination with ibuprofen, diclofenac, ketorolac, naproxen, aspirin, and other NSAIDs is highly undesirable without clinical justification: combined injury to the mucosa increases the likelihood of ulcers and gastrointestinal bleeding.

Diuretics, particularly loop and thiazide diuretics, amphotericin B, and other medications that reduce potassium levels aggravate hypokalemia. This increases the toxicity of cardiac glycosides. Electrolytes need to be monitored rather than merely stating that the combination should be “used with caution.”

Insulin and glucose-lowering medications may become insufficiently effective because prednisolone increases gluconeogenesis and insulin resistance. Therapy is adjusted according to glucose measurements, not simply according to how the patient feels.

Strong CYP3A inducers, including rifampicin, carbamazepine, phenytoin, and phenobarbital, may reduce glucocorticosteroid concentrations and effects. CYP3A inhibitors, including certain azole antifungals, macrolides, and pharmacokinetic enhancers used in antiviral therapy, may increase systemic exposure and the risk of toxicity.

Prednisolone may alter the effect of anticoagulants, so INR monitoring is required when warfarin is used. With cyclosporine, concentrations and toxicity of both agents may increase. Combination with other immunosuppressants increases the risk of infections.

Live vaccines are contraindicated during immunosuppressive therapy. The response to inactivated vaccines may be reduced. Alcohol does not enter into a specific antidotal reaction with prednisolone, but it can increase gastrointestinal irritation, worsen glucose control, and increase the likelihood of medication errors.

Herbal preparations should not automatically be considered neutral either. Products that affect glycemia, blood pressure, potassium, blood coagulation, or CYP3A activity may alter the safety of the treatment regimen. Simultaneous use of several corticosteroids — tablets, inhalers, ointments, drops, and injections — creates a hidden cumulative burden.

Patient Errors

The most dangerous mistake is independently repeating a previously prescribed regimen for any inflammation, rash, joint pain, or cough. Similar symptoms may be caused by allergy, bacterial or fungal infection, an autoimmune process, a drug reaction, or a neoplastic disease. Prednisolone temporarily reduces inflammation but may worsen an infection and delay diagnosis.

Increasing the dose when there is no rapid effect raises metabolic and neuropsychiatric toxicity but does not correct an incorrect diagnosis. Shortening dosing intervals and taking extra tablets is particularly dangerous when liquid formulations are used and when calculating pediatric doses.

A common mistake is to consider every short course in isolation. Several courses within a year, together with a corticosteroid inhaler, nasal spray, ointment, and intra-articular injections, may result in substantial cumulative exposure.

Extending treatment for “just a few more days” increases the risk of adrenal suppression. The opposite mistake is abruptly stopping the medication immediately after improvement without considering the duration of treatment and the starting dose. The patient may interpret the resulting weakness as a return of the disease and independently increase the dose again, creating a cycle of glucocorticoid dependence.

It is dangerous to ignore insomnia, unusual agitation, pronounced edema, excessive thirst, frequent urination, muscle weakness, deterioration of vision, and signs of infection. These are not an inevitable “price of treatment” but possible signs of toxicity requiring reassessment of the regimen.

Overdose and Poisoning

There is no single acute dose of prednisolone that causes severe poisoning in every patient. Unlike paracetamol, prednisolone does not have a typical sequence of occult liver injury developing over specific hours and days. A single accidental overdose of a systemic glucocorticosteroid relatively rarely results in death; repeated excessive dosing and chronic overdose are considerably more dangerous. There is no specific antidote.

After an excessive single dose, nausea, vomiting, abdominal pain or bloating, agitation, insomnia, anxiety, increased blood pressure and glucose, fluid retention, and increased appetite may occur. Susceptible patients may develop pronounced psychiatric reactions, decompensation of diabetes, hypokalemia, and cardiovascular overload.

With repeated excessive dosing, the consequences increase over days and weeks: edema, hypertension, hyperglycemia, infections, psychiatric disturbances, muscle weakness, and electrolyte shifts. Prolonged misuse leads to hypercortisolism syndrome, osteoporosis, myopathy, ocular damage, and adrenal suppression.

A hidden overdose may occur when prednisolone is combined with prednisone or other systemic glucocorticosteroids, when different brand names are used, when the concentration of a solution is misread, when a pediatric dose is calculated incorrectly, or when several topical formulations are used simultaneously. Metabolic inhibitors can increase systemic exposure even without increasing the number of tablets taken.

Management depends on the dose, time since administration, age, comorbidities, and symptoms. Treatment is mainly supportive: monitoring of blood pressure, glucose, electrolytes, mental status, and signs of infection. Self-induced vomiting or attempting to compensate for an overdose by abruptly discontinuing prednisolone is not appropriate. Severe weakness, altered consciousness, psychosis, shortness of breath, repeated vomiting, severe hyperglycemia, or a marked rise in blood pressure requires urgent medical assessment.

Safe Integrative Alternatives to Prednisolone

Prednisolone cannot be replaced with a single herbal preparation for every indication. It is used as a potent anti-inflammatory and immunosuppressive medication in bronchial asthma, severe allergic reactions, autoimmune diseases, inflammatory dermatoses, joint diseases, and other conditions. In adrenal insufficiency, anaphylaxis, a severe asthma attack, cerebral edema, and a life-threatening autoimmune flare, herbal remedies are not an equivalent emergency substitute.

For chronic inflammation of the skin, joints, and soft tissues, the most justified systemic combination is Nigella sativa, Scutellaria baicalensis, and Curcuma longa. Nigella sativa mainly strengthens the antiallergic component, Scutellaria baicalensis affects mast cells and pro-inflammatory signaling pathways, and Curcuma longa complements the systemic anti-inflammatory effect. In edema, damage to the skin barrier, fissures, and delayed tissue repair, it may be appropriate to add Centella asiatica to the combination.

For systemic allergy, urticaria, and allergic manifestations accompanied by cough or bronchial hyperreactivity, a more practical ready-to-use option is Allergy Mixture Capsules.

For allergic rhinitis and rhinosinusitis, the main option is Rhinitis and Rhinosinusitis Mixture Capsules taken orally and ABP-153 applied locally in the nose. If itching, repeated sneezing, watery rhinorrhea, and allergic edema predominate, Allergy Mixture Capsules may be used instead of the rhinosinusitis mixture in combination with ABP-153.

For type 2 bronchial asthma, the most specific preparation is Bronchial Asthma Type 2 Capsules. Clerodendrum serratum may be used as an additional single-herb preparation. These products are intended to control chronic allergic inflammation but do not replace prednisolone and bronchodilators during a severe attack, worsening shortness of breath, or hypoxemia.

For topical use in atopic, contact, and chronic inflammatory dermatitis, an ointment made from Nigella sativa and Scutellaria baicalensis extracts is suitable. To prepare 100 g of ointment, use 5 g of dry Nigella sativa extract, 5 g of dry Scutellaria baicalensis extract, 70 g of coconut oil, 15 g of beeswax, and 5 g of lanolin. Heat the coconut oil, wax, and lanolin in a water bath to 55–60 °C. Triturate the extracts in advance with part of the base, add them with continuous stirring, and transfer the mixture into dark glass containers at approximately 40 °C. For dryness, fissures, and impaired tissue repair, a formulation containing 4 g of Nigella sativa, 4 g of Scutellaria baicalensis, and 2 g of Centella asiatica may be used.

Herbal preparations may reduce the frequency of repeated glucocorticosteroid courses in mild or stable disease. They do not reverse suppression of the hypothalamic-pituitary-adrenal system and do not make abrupt discontinuation of prednisolone safe.

The Real Effectiveness of Prednisolone

Prednisolone is genuinely effective when rapid suppression of marked inflammation, edema, an allergic reaction, or pathological immune activity is required. It can rapidly reduce bronchial obstruction during an asthma exacerbation, the activity of inflammatory rheumatic diseases, severe dermatoses, intestinal inflammation, and certain hematological and nephrological processes. However, the medication often suppresses the inflammatory response rather than eliminating the primary cause of the disease.

The problem begins when prednisolone is prescribed without an accurate diagnosis, used for mild conditions that could be controlled with less toxic agents, or repeated in short courses so frequently that the cumulative exposure effectively becomes chronic. Even short courses may be accompanied by hyperglycemia, increased blood pressure, sleep disturbances, psychiatric reactions, and increased susceptibility to infections. Prolonged treatment is associated with osteoporosis, fractures, cataract, glaucoma, myopathy, diabetes mellitus, infectious complications, and adrenal suppression.

The effectiveness of prednisolone does not eliminate the systemic toxicological cost of treatment. The higher the dose, the longer the course, and the more frequently treatment is repeated, the greater the likelihood of serious complications.

Safety Monitoring During Treatment

During a short course, blood pressure, edema, glucose levels in patients with diabetes or prediabetes, mental state, sleep, and signs of infection should be monitored. Prednisolone may mask fever and local signs of inflammation, so the absence of a high temperature does not exclude an infectious process.

During long-term treatment, body weight, blood pressure, blood glucose or HbA1c, electrolytes, liver and kidney function when clinically indicated, bone health, fracture risk, vision, and intraocular pressure are monitored. When prednisolone is combined with diuretics, cardiac glycosides, and medications that affect potassium, electrolyte monitoring is required. At immunosuppressive doses, assessment of infection risk is particularly important.

Severe weakness, a drop in blood pressure, repeated vomiting, altered consciousness, shortness of breath, generalized edema, severe infection, black stools or vomiting blood, sudden deterioration in vision, psychosis, marked hyperglycemia, and symptoms of thrombosis require immediate medical assessment. During dose reduction, a combination of weakness, nausea, abdominal pain, hypotension, and confusion may indicate adrenal insufficiency.

Correct Discontinuation of Prednisolone and Consequences of Stopping Treatment

After a short course of less than three to four weeks, prednisolone can in many cases be discontinued without gradual dose reduction if the disease is controlled and the patient has no additional factors that suppress adrenal function. After longer use, the risk of hypothalamic-pituitary-adrenal suppression becomes clinically significant, so the dose is reduced gradually.

There is no single tapering regimen suitable for every patient. It depends on the starting dose, duration of treatment, timing of administration, repeated courses, concomitant use of other glucocorticosteroids, and activity of the underlying disease. A high dose can usually be reduced more rapidly, whereas tapering is slowed as the physiological range is approached because this is the stage at which the ability of the adrenal glands to restore endogenous cortisol production becomes apparent.

If the dose is reduced too quickly, two different processes may occur: recurrence of the underlying disease and glucocorticoid withdrawal syndrome. Withdrawal syndrome manifests as pronounced weakness, aching muscles and joints, headache, sleep disturbances, low mood, nausea, and loss of appetite. Adrenal insufficiency may additionally be accompanied by hypotension, vomiting, abdominal pain, hyponatremia, hypoglycemia, and vascular collapse.

Current recommendations suggest assessing adrenal recovery using morning cortisol once the patient has reached a physiological dose and complete discontinuation is being planned. The result should be interpreted as a continuous measure rather than as an absolute cutoff: a higher value favors recovery, an intermediate value requires continuation of the physiological dose and repeat monitoring, and a low value indicates the need to maintain glucocorticosteroid replacement levels. Routine dynamic testing is not required for every patient.

During infection, surgery, trauma, high fever, vomiting, or other physiological stress, a patient with suppressed adrenal function may require a temporary increase in glucocorticoid support. Herbal preparations do not replace a stress dose of glucocorticoid.

A Rational Approach to Treatment

Prednisolone is justified when rapid, strong, and predictable suppression of dangerous inflammation, bronchospasm, an allergic reaction, or an autoimmune process is required. Rejecting it in a critical situation in favor of a more slowly acting herbal regimen is dangerous.

In chronic stable disease, the objective changes: the frequency of exacerbations should be reduced, the need for repeated courses of prednisolone should be decreased, and cumulative toxicity should be minimized. In such cases, alternatives are selected according to the clinical target. For dermatitis, a systemic herbal combination and topical ointment are used; for allergic rhinitis, a targeted mixture and intranasal ABP-153; for type 2 bronchial asthma, a specialized complex and Clerodendrum serratum; for joint inflammation, Nigella sativa, Scutellaria baicalensis, and Curcuma longa.

A herbal alternative is not a method for independently discontinuing prednisolone. The underlying disease is controlled first, then the glucocorticoid burden is gradually reduced, and recovery of adrenal function is assessed separately. The aim of this approach is to preserve the necessary therapeutic effect while reducing the risk of infections, metabolic disturbances, osteoporosis, ocular damage, muscle atrophy, and glucocorticoid dependence.

If you have questions about the subject of this article, you can ask a clinical pharmacologist in the comments or book an appointment using this link: https://asiabiopharm.com/konsultaciii/